Elenco dei contributori

Il progetto “Accademia Europea dell’Innovazione Terapeutica dedicata ai Pazienti” (European Patients Academy on Therapeutic Innovation, EUPATI), i contenuti da questo generati e la piattaforma EUPATI.eu sono il prodotto di una partnership pubblico-privata pan-europea composta da diversi stakeholder, che comprende pazienti e rappresentanti dei pazienti, mondo universitario, organismi di regolamentazione, istituzioni governative indipendenti, organizzazioni no profit e aziende farmaceutiche.

Desideriamo ringraziare i seguenti contributori:

Partner del consorzio

Organizzazioni di pazienti

	European AIDS Treatment Group
	European Genetic Alliance Network
	European Patients Forum
	European Organisation for Rare Diseases

Organizzazioni no profit

	DIA
	The European Forum for Good Clinical Practice
	The European Organisation for Research and Treatment of Cancer
	The Irish Platform for Patient Organisations, Science and Industry
	International Society For Pharmacoeconomics and Outcomes Research

 

Partner accademici

	Biopeople (University of Copenhagen)
	Hibernia College
	The University of Manchester (Nowgen)

 

Industria

	Amgen
	AstraZeneca
	Bayer
	Boehringer Ingelheim
	Bristol-Myers Squibb
	Chiesi
	Esteve
	Farmaindustria
	Genzyme
	GlaxoSmithKline
	Infarma
	Janssen
	Lilly
	Merck
	MSD
	Novartis
	Novo Nordisk
	Pfizer
	Roche
	Sanofi
	UCB
	Verband Forschender Arzneimittelhersteller

Consulenti

• Anke Steckelberg – Università di Amburgo
• Britta Lang – Centro Cochrane tedesco
• Dagmar Friese – Ministero della salute tedesco (BMG)
• Kathy Oliver – International Brain Tumour Alliance (IBTA)
• Ingvil Sæterdal – Centro di conoscenza norvegese per i servizi sanitari; EUNETHTA
• Jean-Jacques Cassiman – Università cattolica di Lovanio
• Jozef Glasa –Facoltà di medicina slovacca
• Karen Facey – University of Glasgow
• Munir Pirmohammed – University of Liverpool
• Peter O’Donnell – European Voice
• Victoria Thomas – National Institute for Health and Clinical Excellence (NICE)
• Vincenzo Costigliola – European Medical Association
• Ysbrand Poortman – World Alliance of Organizations for the Prevention and Treatment of Genetic and Congenital Conditions; International Genetic Alliance of Parent & Patient Organisations

Consulenti per gli affari regolatori

• Anne-Isabel Roth – Bundesinstitut für Arzneimittel und Medizinprodukte (BfArM)
• Birka Lehmann – Bundesinstitut für Arzneimittel und Medizinprodukte (BfArM)
• Cordula Landgraf – Swissmedic
• Isabelle Moulon – European Medicines Agency (EMA)
• Jan MacDonald – Medicines & Healthcare products Regulatory Agency (MHRA)
• June Raine – Medicines & Healthcare products Regulatory Agency (MHRA)
• Luca Pani – Agenzia italiana del farmaco (AIFA)
• Petra Dörr – Swissmedic

Ethics Panel

• Anastassia Negrouk – The European Organisation for Research and Treatment of Cancer (EORTC)
• Andrea Heckenberg
• Bob Wilffert – Rijksuniversiteit Groningen
• Cees Smit – European Genetic Alliances’ Network (EGAN)
• Claudio Castegnaro – Fondazione Paracelso Onlus
• Frank Wells
• Inez de Beaufort
• Pedro Montellano – GAMIAN
• Tanja Krones – Università di Zurigo

Contributori del consorzio

• Alastair Kent – European Genetic Alliances’ Network (EGAN)
• Alberto de Oliveira – Farmaindustria
• Alexandra Williams – Roche
• Amelia Martín Uranga – Farmaindustria
• Amy Hunter – European Genetic Alliances’ Network (EGAN)
• Aoife Gallagher – Eli Lilly
• Anastassia Negrouk – The European Organisation for Research and Treatment of Cancer (EORTC)
• Andreas Schmitt – Chiesi
• Aneta Poznanska – Novartis
• Annamarie Dillon – Genzyme
• Annick Lacroux  – Sanofi
• Antonio Párraga – Esteve
• Barbara Haake – Verband Forschender Arzneimittelhersteller (VFA)
• Bella Starling – Nowgen
• Birka Lehmann – Bundesinstitut für Arzneimittel und Medizinprodukte (BfArM)
• Brigitte Franke-Bray – DIA
• Catherine Levinson-Bates – Merck KGaA
• Cecilia Cariño Morales – DIA
• Celine Lewis – European Genetic Alliances’ Network (EGAN)
• Christine Mullan-Jensen – Novo Nordisk
• Cor Oosterwijk – European Genetic Alliances’ Network (EGAN)
• Cornelius Erbe – Verband Forschender Arzneimittelhersteller (VFA)
• Cristina Moro – Esteve
• Daniel Gil – Farmaindustria
• Danielle Flores – European Patients Forum (EPF)
• Daphnee Pushparajah – UCB
• David Haerry – European AIDS Treatment Group (EATG)
• Detlef Niese – Novartis
• Dominique Roome – Sanofi
• Donald Husereau – International Society For Pharmacoeconomics and Outcomes Research (ISPOR)
• Dr. Petra Dörr – Swissmedic
• Eibhlin Mulroe – The Irish Platform for Patient Organisations, Science and Industry (IPPOSI)
• Elzbieta Talarczyk – Bristol-Myers Squibb
• Ewa Kiersztyn – Infarma
• Fanny Senez – European Forum for Good Clinical Practice (EFGCP)
• Francois Houyez – European Organisation for Rare Diseases (EURORDIS)
• Giorgio Barbareschi – European AIDS Treatment Group (EATG)
• Giulio Corbelli – European AIDS Treatment Group (EATG)
• Grainne Crowley – Eli Lilly
• Heidi Scherz – DIA
• Henri Caplain – Sanofi
• Holger Maria Rohde – Merck KGaA
• Iciar Sanz de Madrid – Farmaindustria
• Ilaria Piuzzi – Janssen
• Ingrid Heyne – European Forum for Good Clinical Practice (EFGCP)
• Ingrid Jenisch – Patvocates
• Ingrid Klingmann – European Forum for Good Clinical Practice (EFGCP)
• Inkatuuli Heikkinen – DIA
• Irmi Gallmeier – Roche
• Isabel Ashburner – Hibernia College
• Jan Geissler – Patvocates
• Jeremy Whitty – Hibernia College
• Jessica Paciej – DIA
• John Lenehan – Hibernia College
• Joseph Lama – Amgen
• Jytte Lyngvig – DIA
• Kamila Kozbial – Novartis
• Kay Warner – GlaxoSmithKline
• Ken Rogens – The Irish Platform for Patient Organisations, Science and Industry (IPPOSI)
• Kim Crescenzi – GlaxoSmithKline
• Kim Wever – European Genetic Alliances’ Network (EGAN)
• Krzysztof Kaluzny – Infarma
• Laurence Vroye – UCB
• Liuska Sanna – European Patients Forum (EPF)
• Luca Tolda – Merck KGaA
• Ludivine De Menten – UCB
• Lukasz Sedrowicz – Bristol-Myers Squibb
• Magdalena Tonder – UCB
• Maria Mavris – European Organisation for Rare Diseases (EURORDIS)
• Mario Scuri – Chiesi
• Martin Wright – Amgen
• Mary Uhlenhopp – Amgen
• Mathias Schuler – Pfizer
• Matthew May – DIA
• Matthias Gottwald – Bayer
• Michael Hamann  – Amgen
• Mike Hardman – AstraZeneca
• Nadia Naaman – International Society For Pharmacoeconomics and Outcomes Research (ISPOR)
• Nancy Hamilton – European Organisation for Rare Diseases (EURORDIS)
• Nicola Bedlington – European Patients Forum (EPF)
• Nicole Schroeter – Patvocates
• Niels Westergaard – University of Copenhagen (Biopeople)
• Oleksandr Martynenko – European AIDS Treatment Group (EATG)
• Olga Krylova – Pfizer
• Patricio Múrias dos Santos  – Merck KGaA
• Pawel Wakor – Infarma Poland
• Per Helboe – University of Copenhagen
• Per Spindler – University of Copenhagen (Biopeople)
• Rob Camp – European Organisation for Rare Diseases (EURORDIS)
• Robert Kroes – Eli Lilly
• Roderigo Sanchez – DIA
• Roslyn Schneider – Pfizer
• Roz Round – Roche
• Silvano Berioli – European Forum for Good Clinical Practice (EFGCP)
• Silvia Cammarat – Italian Medicines Agency (AIFA)
• Solange Rohou – AstraZeneca
• Sophie Vanalethem – UCB
• Søren Eik Skovlund – Novo Nordisk
• Stéphane Lejeune – The European Organisation for Research and Treatment of Cancer (EORTC)
• Su-Gwan Tham – Nowgen
• Susan Parsons – Nowgen
• Susanna Leto – Novartis
• Susanne Neustadt – Pfizer
• Tamás Bereczky – European AIDS Treatment Group (EATG)
• Toni Parraga – Esteve
• Virginie Delwart – Janssen
• Volker Barkmann – Boehringer Ingelheim
• Walter Atzori – European Patients Forum (EPF)
• Wolf See – Bayer
• Xavier Hormaechea – UCB
• Zaida Costa – UCB

Leggibilità

Luto è un’agenzia di comunicazione sanitaria, specializzata nella progettazione di comunicazioni semplici tramite una buona elaborazione delle informazioni. Forti di un’esperienza decennale fondata sul rigore accademico, comprendiamo in che modo gli utenti interagiscono, leggono e si pongono nei confronti delle informazioni e dei prodotti sanitari. Le nostre metodologie collaudate consentono di migliorare la leggibilità e la fruibilità dei diversi tipi di comunicazioni destinate a pazienti, assistenti sanitari, medici e accademici

Traduzione

Lionbridge è un’azienda di localizzazione a livello mondiale che unisce il know-how linguistico alle capacità operative per interagire con i propri clienti in tutto il mondo, ottenendo i migliori risultati.

Contributori esterni al consorzio

• Agencia española de medicamentos y productos sanitarios (AEMPS)
• Anne Chirkova
• Anne-Sophie Lapointe
• Antje Schütt – Technologie- und Methodenplattform für die vernetzte medizinische Forschung (TMF)
• Antonina Smolina
• Blanca Rubio – Asociación Madrileña de Lupus
• Caroline Harmingnie
• Claas Röhl – NF Kinder
• David Trigos Herraez
• Dominika Bijos
• Hanna Milczarek
• Joanna Rybka
• Kinga Marcinek – Fundacja My pacjenci
• Margaret Webb
• Mercede Maderuelo – Federación de diabéticos españoles
• Michael Scherz – Scherz Pharma Consulting
• Miloš Stojković
• Moreno Busolin
• Paolo Gorgoni
• Pascal Doppmann
• Patrick Miqueu
• Petra Baddack
• Polina Afanasyeva
• Roberto  Saldaña – Confederación de asociaciones de enfermos de Crohn y colitis ulcerosa de España
• Sara Pérez
• Siobhan Gaynor – Molecular Medicine, Ireland
• Stan Mackowiakl – Federation of Polish Patients
• Tatyana Khan – ITPCru
• Vanessa Lyons – Health Products Regulatory Authority (HPRA)
• Witold Michalek – Federation of Polish Patients